US biotechnology firm Novelos Therapeutics has filed an Investigational New Drug application with the Food and Drug Administration for NOV-205, its second clinical-stage compound to be evaluated as a monotherapy for chronic hepatitis C patients who have failed to respond to pegylated interferon plus ribavirin therapy.
The agent, which is designed to act as a hepatoprotective with immunomodulating and antiviral activity, has already been approved in the Russian Federation based on studies in hepatitis B and C in which it reduced or eliminated viral levels and significantly improved abnormal liver enzyme values. The USA-based Phase Ib trial aims to expand the safety database for NOV-205 and assess its effects on the same key efficacy-related endpoints that showed improvement in the Russian studies, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze